FDA staff members recommended the approval of Sanofi-Aventis' Multaq for select patients with atrial fibrillation. The endorsement is based on clinical evidence that Multaq can significantly reduce hospitalizations due to heart arrhythmia. A panel of experts will meet Wednesday to evaluate the product for approval.

Full Story:
Bloomberg, Google

Related Summaries